3 Asian Stocks Estimated To Be Trading Below Fair Value By Up To 49.5%

As global markets navigate a complex landscape marked by interest rate adjustments and mixed economic signals, Asia's stock markets have faced their own set of challenges, with Japan experiencing significant rate hikes and China's growth indicators showing signs of stagnation. In this environment, identifying undervalued stocks can be particularly appealing to investors looking for opportunities that may offer potential value relative to current market valuations.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name	Current Price	Fair Value (Est)	Discount (Est)
Xi'an NovaStar Tech (SZSE:301589)	CN¥154.88	CN¥302.77	48.8%
Sany Heavy Equipment International Holdings (SEHK:631)	HK$8.50	HK$16.36	48.1%
Mobvista (SEHK:1860)	HK$15.40	HK$30.69	49.8%
Kuraray (TSE:3405)	¥1600.00	¥3167.00	49.5%
H.U. Group Holdings (TSE:4544)	¥3364.00	¥6592.59	49%
FIT Hon Teng (SEHK:6088)	HK$5.70	HK$11.22	49.2%
Daiichi Sankyo Company (TSE:4568)	¥3332.00	¥6544.37	49.1%
CURVES HOLDINGS (TSE:7085)	¥795.00	¥1573.75	49.5%
Cowell e Holdings (SEHK:1415)	HK$27.92	HK$55.44	49.6%
Beijing HyperStrong Technology (SHSE:688411)	CN¥259.90	CN¥515.12	49.5%

Click here to see the full list of 273 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let's dive into some prime choices out of the screener.

MicroPort Scientific (SEHK:853)

Overview: MicroPort Scientific Corporation, with a market cap of HK$19.88 billion, is involved in innovating, manufacturing, and marketing medical devices across the People's Republic of China, Europe, the Middle East and Africa, Japan, and other international markets.

Operations: The company's revenue is primarily derived from its Orthopedics Devices Business ($249.94 million), Cardiac Rhythm Management Business ($221.36 million), Cardiovascular Devices Business excluding CRM, Surgical Robot Device, and Heart Valve Business ($161.90 million), Endovascular and Peripheral Vascular Devices Business ($158.41 million), Neurovascular Devices Business ($102.90 million), Structural Heart Disease Business ($51.25 million), and Surgical Robot Devices Business ($46.54 million).

Estimated Discount To Fair Value: 11.2%

MicroPort Scientific is trading at HK$10.39, below its estimated fair value of HK$11.7, indicating potential undervaluation based on discounted cash flow analysis. Despite a low forecasted return on equity of 8.8%, its earnings are expected to grow significantly and become profitable within three years, surpassing average market growth rates. Recent governance changes aim to enhance decision-making processes, potentially strengthening the company's strategic direction and financial management capabilities in the long term.

• Insights from our recent growth report point to a promising forecast for MicroPort Scientific's business outlook.
• Dive into the specifics of MicroPort Scientific here with our thorough financial health report.

Beijing HyperStrong Technology (SHSE:688411)

Overview: Beijing HyperStrong Technology Co., Ltd. specializes in the design, development, integration, and operation of energy storage power stations in China, with a market cap of CN¥46.81 billion.

Operations: Revenue Segments (in millions of CN¥):

Estimated Discount To Fair Value: 49.5%

Beijing HyperStrong Technology, with a current trading price of CN¥259.9, is significantly undervalued compared to its estimated fair value of CN¥515.12 based on discounted cash flow analysis. The company's revenue and earnings are forecast to grow substantially, outpacing the broader Chinese market's growth rates. Despite recent share price volatility, recent earnings reports show strong performance with sales reaching CN¥7.91 billion and net income doubling year-over-year to CN¥622.6 million by September 2025.

• The growth report we've compiled suggests that Beijing HyperStrong Technology's future prospects could be on the up.
• Delve into the full analysis health report here for a deeper understanding of Beijing HyperStrong Technology.

Chenbro Micom (TWSE:8210)

Overview: Chenbro Micom Co., Ltd. is involved in the R&D, design, manufacture, processing, and trading of computer peripherals and systems globally, with a market cap of NT$116.11 billion.

Operations: The company's revenue from computer peripherals amounts to NT$19.13 billion.

Estimated Discount To Fair Value: 25.1%

Chenbro Micom, trading at NT$955, is undervalued compared to its fair value estimate of NT$1,275.28. The company shows strong financial health with third-quarter sales rising to NT$5.66 billion from NT$4.27 billion year-over-year and net income increasing to NT$993.32 million from NT$643.77 million. Earnings are projected to grow significantly over the next three years, surpassing Taiwan's market growth rates despite recent share price volatility.

• The analysis detailed in our Chenbro Micom growth report hints at robust future financial performance.
• Click here to discover the nuances of Chenbro Micom with our detailed financial health report.

Key Takeaways

• Dive into all 273 of the Undervalued Asian Stocks Based On Cash Flows we have identified here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.